AGIO
Agios Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$33.10
−0.09%Aug 13, 2026, 07:31 UTC
Assenagon Asset Management S.A. increased its stake in Agios Pharmaceuticals, Inc. by 54.8% during the second quarter, acquiring 36,802 additional shares, according to a Form 13F filing.
Source:Jul 30, 2026, 10:30 UTC
Agios Pharmaceuticals advanced AG-236 into Phase 2/3 development for polycythemia vera.
Source:Jul 30, 2026, 10:30 UTC
Agios Pharmaceuticals licensed cevidoplenib for immune thrombocytopenia, diversifying its late-stage pipeline.
Source:Jul 30, 2026, 10:30 UTC
Agios Pharmaceuticals reported a strong U.S. commercial launch of AQVESME in thalassemia, with 442 cumulative prescriptions written as of June 30, 2026.
Source:Jul 30, 2026, 10:30 UTC
Agios Pharmaceuticals reported financial results for the second quarter ended June 30, 2026, with mitapivat worldwide net revenues of $44.7 million and cash position of $964.8 million.
Jul 21, 2026, 11:58 UTC
Agios Pharmaceuticals halted development of its sickle cell disease treatment after Phase 2 trial results failed to show differentiation.
Jul 7, 2026, 11:00 UTC
The U.S. FDA accepted Agios Pharmaceuticals' supplemental New Drug Application for mitapivat in sickle cell disease with Priority Review.
Jun 13, 2026, 18:07 UTC
Agios Pharmaceuticals presented new clinical data for mitapivat across thalassemia and sickle cell disease at the 2026 European Hematology Association Congress in Stockholm.
Source:Jun 2, 2026, 15:25 UTC
Agios Pharmaceuticals secures global rights to cevidoplenib, a late-stage candidate for immune thrombocytopenia (ITP), from an undisclosed partner.
Source:Jun 1, 2026, 14:46 UTC
Agios Pharmaceuticals halts development of tebapivat for lower-risk myelodysplastic syndromes after a phase IIb trial fails to meet efficacy endpoints.
Source:Jun 1, 2026, 09:00 UTC
Agios Pharmaceuticals entered an exclusive global license agreement with Oscotec to develop and commercialize the SYK inhibitor cevidoplenib.